Therapeutic targets of triple-negative breast cancer: a review
about
A Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1.Phytoagent Deoxyelephantopin and Its Derivative Inhibit Triple Negative Breast Cancer Cell Activity through ROS-Mediated Exosomal Activity and Protein Functions.Systematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on Genome-Wide RNA Interference TranscriptomesFunctional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cellsBreast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal CarcinomasTriple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Curcumin Ameliorates Cisplatin-Induced Nephrotoxicity and Potentiates Its Anticancer Activity in SD Rats: Potential Role of Curcumin in Breast Cancer Chemotherapy.Targeted therapies in breast cancer: New challenges to fight against resistance.Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer.Modeling Intercellular Communication as a Survival Strategy of Cancer Cells: An In Silico Approach on a Flexible Bioinformatics Framework.Metastatic breast cancer: The Odyssey of personalization.Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy.Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells.Optical and Magnetic Resonance Imaging Using Fluorous Colloidal Nanoparticles.Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer.The development of activatable lytic peptides for targeting triple negative breast cancer.YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways.VSP-17, a New PPARγ Agonist, Suppresses the Metastasis of Triple-Negative Breast Cancer via Upregulating the Expression of E-Cadherin.Short SULF1/SULF2 splice variants predominate in mammary tumours with a potential to facilitate receptor tyrosine kinase-mediated cell signalling.MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.miRNA-135b Contributes to Triple Negative Breast Cancer Molecular Heterogeneity: Different Expression Profile in Basal-like Versus non-Basal-like Phenotypes.Targeted therapy of triple negative MDA-MB-468 breast cancer with curcumin delivered by epidermal growth factor-conjugated phospholipid nanoparticles.Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells.The "Yin and Yang" of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers
P2860
Q26752846-BD51884E-2CD1-4412-8DDA-11523356D806Q33768248-4CE739FA-0733-43DE-8150-39317373F19BQ33851617-F9580FA8-8282-4B9D-8C3F-CB1106B79950Q36293047-2849B6FA-1247-425D-94C1-E297E05C612AQ36496096-18D71D81-0CDD-4D77-A3D0-4C7CB2A97D9FQ36544129-DC3532CC-A349-4E0C-9A72-5F8DD9787F77Q36823916-AB2C738B-4D54-4E5E-9AB3-2D2DA574168FQ37645090-AB6B5632-9230-43A8-A3F8-FBE5DE1C7146Q37736102-58791A81-C9E4-4F27-A966-C72D042C8CAEQ37743048-0BA43324-37E5-444B-B445-E00D92148A1DQ38714359-3A659CB9-8FB3-4A1A-94A2-49E17CE36628Q38748639-C859FFF5-403D-48D9-B125-4D3976F372DEQ38892442-F31FADBB-5D61-4D56-B88F-89C9F2C2432CQ38901163-D1CBA16A-069E-4B5D-90C1-9DAE0F5DD3FBQ39000232-C66FE1B3-94B0-454A-9CDD-CCB922595AE3Q40983668-4F9D46D0-2724-45F6-A77B-36E9D94CDFB8Q41449799-6EC43095-1BF3-4D7B-A6B4-76DA7AE340DCQ42275833-E67BBE28-500E-43EB-B929-1D617BCDEA6CQ44076458-1CA1F109-D5AC-4102-8827-6BBA782254E4Q46952566-0730B372-FEEE-42F2-9E9A-AE497609B61EQ47153328-5968624D-E41A-4605-BF3C-F71CCB188179Q50116117-3A6BDA72-DD61-4293-9AC2-253F23FFDACAQ51706240-3DAA9BE0-ED33-4697-8A2E-4102A82C744CQ54977971-FE4F114C-A8F2-42A3-AC25-FDBAEB903DC9Q55020981-46C7860B-4D5B-4376-99B9-84DC30F2EE5CQ55103330-350160AD-470B-4571-8C93-5649B5501D15Q55339147-BB390E4F-A066-4614-A14B-56B17FCBE75EQ58702607-CF0E88B3-9466-435D-9174-78C59DBE59AE
P2860
Therapeutic targets of triple-negative breast cancer: a review
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Therapeutic targets of triple-negative breast cancer: a review
@ast
Therapeutic targets of triple-negative breast cancer: a review
@en
Therapeutic targets of triple-negative breast cancer: a review
@nl
type
label
Therapeutic targets of triple-negative breast cancer: a review
@ast
Therapeutic targets of triple-negative breast cancer: a review
@en
Therapeutic targets of triple-negative breast cancer: a review
@nl
prefLabel
Therapeutic targets of triple-negative breast cancer: a review
@ast
Therapeutic targets of triple-negative breast cancer: a review
@en
Therapeutic targets of triple-negative breast cancer: a review
@nl
P2093
P2860
P3181
P356
P1476
Therapeutic targets of triple-negative breast cancer: a review
@en
P2093
Mangala Lahkar
Neeraj Sinha
Nikunj Sethi
Nitin A Mundhe
Vinayak S Jamdade
P2860
P304
P3181
P356
10.1111/BPH.13211
P407
P577
2015-07-30T00:00:00Z